PRL and cancer: Many of the remaining 20% of experimental PRL-induced cancers exhibited elevated pAKT, but not pERK1/2, consistent with driver mutations in the phosphatidylinositol-3-kinase pathway, common in many clinical ER+ cancers (63, 65, 66).